Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05013554 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory… | Phase 1 | terminated | Aug 19, 2021 | Sanofi | not stated | Not stated |
| NCT00466830 | Psychological and Social Factors and Risk Chronic Pain After Surgery in Women With Breast…(SDPM) | — | withdrawn | Apr 27, 2007 | Institut Bergonié | not stated | Not stated |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+)…(AMEERA-5) | Phase 3 | terminated | Jul 20, 2020 | Sanofi | The study was terminated based on the review by an independent data monitoring committee of the… | Safety / toxicity |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for… | Phase 2 | terminated | Sep 10, 2025 | National Cancer Centre, Singapore | Difficulty in enrolling patients with the illness under study. | Enrollment / accrual |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | CytoDyn, Inc. | Study terminated prematurely due to business reasons. Participants are no longer examined or… | Sponsor / business decision |
| NCT00210145 | Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast…(ASE K SEIN) | — | withdrawn | Sep 21, 2005 | Institut Bergonié | not stated | Not stated |
| NCT04815083 | Fluorescence Imaging of Carcinoma During Breast Conserving Surgery | Phase 3 | terminated | Mar 24, 2021 | SBI ALApharma Canada, Inc. | Study terminated due to closure of Sponsor business | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | Phase 2 | terminated | Apr 18, 2018 | University of Alabama at Birmingham | Study accrual ended early due to the FDA approval of tucatinib in metastatic HER2+ breast cancer | Enrollment / accrual |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Alaunos Therapeutics | The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower… | Enrollment / accrual |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | Phase 1 / Phase 2 | terminated | Jun 21, 2016 | Samuel Achilefu | Before LS301's licensing and reformulation, 9 patients received LS301-HSA (Phase 1a) , but since no… | Enrollment / accrual |
| NCT04756765 | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | Phase 2 | withdrawn | Feb 16, 2021 | Stanford University | Due to changes in the treatment landscape, the study faced significant recruitment challenges. As… | Enrollment / accrual |
| NCT05560685 | SMART-ER: Symptom Monitoring With Patient-reported Outcomes(SMART-ER) | N/A | terminated | Sep 29, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding | Funding |
| NCT05623488 | CAR T Cells in Mesothelin-Expressing Breast Cancer | Phase 1 | terminated | Nov 21, 2022 | University of Pennsylvania | Feasibility Concerns | Other (stated, no rule matched) |
| NCT04740918 | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a…(KATE3) | Phase 3 | terminated | Feb 5, 2021 | Hoffmann-La Roche | Due to low enrollment, the Sponsor decided to prematurely terminate the study | Enrollment / accrual |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast…(PEAR-TNBC) | — | terminated | Jun 28, 2022 | Ourotech, Inc. | Lack of funding | Funding |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2023 | Artiva Biotherapeutics, Inc. | Corporate business decision | Sponsor / business decision |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT04227327 | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer…(HERMIONE-7) | Phase 2 | terminated | Jan 13, 2020 | University of Milano Bicocca | Difficulties in patient recruitment | Enrollment / accrual |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or…(Panthera) | Phase 1 | terminated | Aug 1, 2019 | Cancer Trials Ireland | Accrual rate to date was too low to finish the trial in a reasonable timeframe | Enrollment / accrual |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | Phase 2 | terminated | Mar 29, 2022 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed. | Enrollment / accrual |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | Early Phase 1 | withdrawn | Feb 7, 2024 | Virginia G. Kaklamani | Unable to enroll to study. | Enrollment / accrual |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT01722890 | CharactHer. ICORG 12-09, V3 | — | terminated | Nov 7, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT01726322 | Ovarian Reserve in Premenopausal Breast Cancer | — | terminated | Nov 14, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT03816839 | Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal…(AMEERA-2) | Phase 1 | terminated | Jan 25, 2019 | Sanofi | Sponsor decision to prematurely stop the study, not linked to any safety concern. | Safety / toxicity |
| NCT05511844 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | Phase 1 | terminated | Aug 23, 2022 | Orum Therapeutics USA, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05031065 | Prognostic Indicators for Radiation-induced Breast Fibrosis | — | terminated | Sep 1, 2021 | AHS Cancer Control Alberta | Loss of Funding | Funding |
| NCT03248492 | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab… | Phase 2 | terminated | Aug 14, 2017 | Daiichi Sankyo | The last participant was transitioned to alternative study. | Other (stated, no rule matched) |
| NCT06852560 | A Trial Assessing Feasibility of Allostatic Load Biomarkers and CVD Risk Among Black…(GEM) | N/A | withdrawn | Feb 28, 2025 | University of Florida | PI has left institution | Other (stated, no rule matched) |
| NCT03941223 | Regional Anesthesia for Breast Surgery | N/A | withdrawn | May 7, 2019 | Azienda USL Reggio Emilia - IRCCS | study never started | Other (stated, no rule matched) |
| NCT01231932 | Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and… | — | terminated | Nov 1, 2010 | National Institute of Nursing Research (NINR) | Principal Investigator (PI) of this study is retiring. | Investigator |
| NCT05447910 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative… | — | terminated | Jul 7, 2022 | Mayo Clinic | insufficient funding | Funding |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2021 | M.D. Anderson Cancer Center | Termination was requested by study supporter IKENA oncology | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT05243641 | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and… | Phase 1 / Phase 2 | terminated | Feb 17, 2022 | M.D. Anderson Cancer Center | Sponsor Withdrew Support | Other (stated, no rule matched) |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting…(neoBREASTIM) | Phase 1 / Phase 2 | terminated | Oct 4, 2023 | Institut Curie | insufficient recruitment | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT04251169 | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer…(TATEN) | Phase 2 | terminated | Jan 31, 2020 | SOLTI Breast Cancer Research Group | The enrollment was stopped prematurely due to the lack of funding | Enrollment / accrual |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients…(PERSEVERE) | Phase 2 | terminated | Apr 19, 2021 | Bryan Schneider, MD | Funder Decision | Other (stated, no rule matched) |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 15, 2025source: clinicaltrials